REFERENCES:
1. DALIRESP (roflumilast)
Prescribing Information. Forest Pharmaceuticals, Inc. St. Louis, MO.
2. Global Initiative for Chronic Obstructuve Lung Disease. Global strategy for the
diagnosis, management, and prevention of chronic obstructive pulmonary disease.
Updated 2010.
http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf.
Accessed November 15, 2011.
3. US Food and Drug Administration. Atrovent approval history (NDA 019085, 1986).
Drugs@FDA.
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed
July 21, 2011.
4. Data on file. Forest Laboratories, Inc.
5. Calverley PMA, Rabe KF, Goehring U-M, Kristiansen S, Fabbri LM, Martinez FJ;
for the M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive
pulmonary disease: two randomised clinical trials.
Lancet. 2009;374:685-694.